Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on September 14, 2020, at 10:00 a.m. ET. The event will be accessible via a webcast on the company's website under the 'Events & Presentations' section. Dynavax is focused on developing novel vaccines, including its first commercial product, HEPLISAV-B®, launched in February 2018, aimed at preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a $3.4 million grant from the Bill & Melinda Gates Foundation to scale up production of its CpG 1018 adjuvant, which supports COVID-19 vaccine development. This funding aims to increase manufacturing capacity to 750 million doses annually, potentially aiding global vaccine distribution. CEO Ryan Spencer emphasized the importance of adjuvants in enhancing vaccine effectiveness. CpG 1018 has a proven track record with the FDA-approved HEPLISAV-B hepatitis B vaccine.
Dynavax Technologies Corporation (DVAX) reported second quarter 2020 financial results, revealing net product revenue of $2.4 million, a decline from $8.3 million in Q2 2019, primarily due to a significant drop in adult hepatitis B vaccine utilization caused by the COVID-19 pandemic. Despite this setback, the company's prospects remain positive with ongoing collaborations to develop adjuvanted vaccines, including COVID-19. The net loss for the quarter was $51.6 million, or $0.53 per share, with a cash position of $200.7 million as of June 30, 2020.
Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company, known for developing novel vaccines, launched HEPLISAV-B® in February 2018, and is advancing CpG 1018 as a vaccine adjuvant with partnerships focused on vaccines for COVID-19, pertussis, and universal influenza. Access to the webcast will be available on their website, with a replay for 30 days post-event.
Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Julie Eastland and Brent MacGregor to its Board of Directors. Julie brings over 25 years of experience in financial roles within biotechnology, while Brent has 20 years in global strategy and commercial operations, particularly in vaccines. Both are expected to provide strategic insights to strengthen Dynavax's position in the vaccine market, building on their established products like HEPLISAV-B and CpG 1018.
Dynavax Technologies (NASDAQ: DVAX) has announced a collaboration with Mount Sinai to develop a universal influenza vaccine. Funded by NIAID's CIVICs program, this initiative aims to combine Dynavax's CpG 1018 adjuvant with Mount Sinai's chimeric hemagglutinin technology. Current flu vaccines have variable effectiveness (10-60%), and this collaboration seeks to create a vaccine that may provide broader and longer-lasting protection against all strains of influenza. The program is set to support an IND application for Phase I clinical trials.
Dynavax Technologies Corporation has partnered with Times Pharmacy and Hep Free Hawaii to provide HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine, to at-risk populations in Hawaii, particularly people with diabetes. The vaccine is essential as individuals with diabetes are at higher risk for hepatitis B and related liver cancer. Vaccination aims to combat the high liver cancer rates in Hawaii, where it's the second highest in the U.S. HEPLISAV-B requires only two doses within a month, offering greater efficacy than previous vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on June 25, 2020, at 10:50 a.m. E.T. Interested parties can access the presentation through the 'Events & Presentations' section on Dynavax's investor website. Dynavax is focused on developing and commercializing novel vaccines, including HEPLISAV-B®, a Hepatitis B vaccine. The company is also advancing its CpG 1018 adjuvant for COVID-19 and pertussis vaccines. For more details, visit www.dynavax.com.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced the completion of enrollment for a clinical trial evaluating HEPLISAV-B® in adults with end-stage renal disease (ESRD) undergoing hemodialysis, enrolling 119 patients. The company anticipates final immunogenicity data in Q4 2020. The study aims to assess a new 4-dose regimen of HEPLISAV-B, which could offer an important vaccination alternative in this high-risk population. However, safety and effectiveness of the vaccine have not yet been established in these patients.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on June 9 at 12:00 p.m. C.T. The presentation will be accessible via the Company’s website under the 'Events & Presentations' section. Dynavax is known for developing novel vaccines, including HEPLISAV-B, approved in 2018 for hepatitis B prevention in adults. The company is also advancing CpG 1018 as a vaccine adjuvant through partnerships.
FAQ
What is the current stock price of Dynavax Technolo (DVAX)?
What is the market cap of Dynavax Technolo (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
